RNA Avidity Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RNA

Price (delayed)

$22.79

Market cap

$1.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.35

Enterprise value

$659.4M

Avidity Biosciences, Inc. is driven to change lives with a new class of therapies called Antibody Oligonucleotide Conjugates (AOCs) that are designed to overcome current limitations of oligonucleotide therapies in ...

Highlights
The gross profit has soared by 58% YoY and by 4.5% QoQ
RNA's revenue has surged by 58% year-on-year and by 4.5% since the previous quarter
RNA's EPS has soared by 69% YoY but it is down by 19% from the previous quarter
Avidity Biosciences's debt has increased by 27% YoY but it has decreased by 4% from the previous quarter
RNA's net income has shrunk by 149% YoY and by 23% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aviditybiosciences.com
Peers: PTCT ACOR SRPT CPRX

Key stats

What are the main financial stats of RNA
Market
Shares outstanding
46.9M
Market cap
$1.07B
Enterprise value
$659.4M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.17
Price to sales (P/S)
102.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.57
Earnings
Revenue
$9.62M
EBIT
-$95.75M
EBITDA
-$95.2M
Free cash flow
-$83.94M
Per share
EPS
-$2.35
Free cash flow per share
-$1.94
Book value per share
$10.48
Revenue per share
$0.22
TBVPS
$9.84
Balance sheet
Total assets
$425.92M
Total liabilities
$31.04M
Debt
$877,000
Equity
$394.88M
Working capital
$399.54M
Liquidity
Debt to equity
0
Current ratio
18.82
Quick ratio
18.44
Net debt/EBITDA
4.3
Margins
EBITDA margin
-990%
Gross margin
100%
Net margin
-995.7%
Operating margin
-996.2%
Efficiency
Return on assets
-28.1%
Return on equity
-30.6%
Return on invested capital
N/A
Return on capital employed
-23.7%
Return on sales
-995.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RNA stock price

How has the Avidity Biosciences stock price performed over time
Intraday
2.06%
1 week
-5.94%
1 month
-3.92%
1 year
-26.15%
YTD
-10.7%
QTD
-7.47%

Financial performance

How have Avidity Biosciences's revenue and profit performed over time
Revenue
$9.62M
Gross profit
$9.62M
Operating income
-$95.8M
Net income
-$95.75M
Gross margin
100%
Net margin
-995.7%
The operating income has plunged by 181% YoY and by 23% from the previous quarter
RNA's net income has shrunk by 149% YoY and by 23% QoQ
RNA's operating margin has dropped by 78% year-on-year and by 18% since the previous quarter
The gross profit has soared by 58% YoY and by 4.5% QoQ

Growth

What is Avidity Biosciences's growth rate over time

Valuation

What is Avidity Biosciences stock price valuation
P/E
N/A
P/B
2.17
P/S
102.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.57
RNA's EPS has soared by 69% YoY but it is down by 19% from the previous quarter
The equity rose by 49% QoQ and by 23% YoY
The P/B is 28% below the last 4 quarters average of 3.0
RNA's revenue has surged by 58% year-on-year and by 4.5% since the previous quarter
RNA's P/S is 4.1% above its last 4 quarters average of 98.5

Efficiency

How efficient is Avidity Biosciences business performance
RNA's ROS has plunged by 79% YoY and by 18% from the previous quarter
RNA's ROA has plunged by 62% YoY and by 16% from the previous quarter
The ROE has contracted by 15% from the previous quarter and by 2.3% YoY

Dividends

What is RNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNA.

Financial health

How did Avidity Biosciences financials performed over time
RNA's total assets is up by 47% QoQ and by 23% YoY
RNA's quick ratio is down by 26% YoY but it is up by 8% from the previous quarter
Avidity Biosciences's debt is 100% less than its equity
The equity rose by 49% QoQ and by 23% YoY
Avidity Biosciences's debt has increased by 27% YoY but it has decreased by 4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.